52 – Phase 2 Trial Design & Endpoints (S4E7)

Welcome back. Glad to have you here for another
deep dive. Today, we're going to be tackling
something that's really essential in the world
of medicine. We're going to be talking about
phase two clinical trials. And we're focusing
on, I think a lot of you out there are really
interested in understanding how do researchers
actually design these trials, especially when
it comes to figuring out if a new drug actually
works. So we'll be focusing on those crucial
elements, endpoints, and statistical power. Yeah,
that's that's a great place to start phase two
trials or where things start to get really interesting
They bridge that gap between you know Those initial
safety tests that are done in phase one and then
the larger confirmatory trials that happen in
phase three So this is where we really start
to see if a drug can truly deliver on its promise
I love that, you know deliver on its promise
It reminds us that there's so much hope riding
on these trials, but before we get too ahead
of ourselves Let's kind of break down what makes
a phase two trial tick One thing that always
stands out to me is this concept of control groups.
Why are they so important? Yeah, control groups
are absolutely essential because what they do
is they allow us to isolate the true effects
of a new drug. They let us compare what happens
to patients who are receiving the new treatment
versus those who are receiving either a placebo
or the current standard of care or sometimes
even no treatment at all. So it helps us rule
out any other factors that might be influencing
the results, you know. besides the treatment
itself. OK, that makes sense. But what about
the ethics of giving some patients a placebo?
I mean, isn't it kind of a dilemma if we think
that this new drug might actually be helpful?
Yeah, you've hit on a really, really crucial
point. The use of placebos is always very, very
carefully considered, especially in situations
where there is an existing treatment available.
And it's all about balancing the need for rigorous
scientific evidence with the well -being of the
patients who are participating in the trial.
So researchers and ethical review boards, they
grapple with this constantly, weighing the potential
benefits of the new treatment against the risks
of using a placebo. And in some cases, you know,
using a placebo might be deemed unethical, and
the new drug would be compared to the existing
standard of care instead. That's really insightful.
I mean, it really helps me understand the complexities
involved in designing these trials. So we've
got our treatment group, and we've got our control
group. How do we decide? who goes where. I mean,
isn't there a risk of bias if the researchers
are kind of handpicking patients for each group?
Absolutely. And that's where randomization comes
in. It's essentially like flipping a coin to
decide which group each patient will be assigned
to. And by doing this, what we do is we ensure
that the groups are as similar as possible at
the start of the trial. It minimizes the chances
that any differences we see in the results are
due to pre -existing factors rather than the
treatment itself. It levels the playing field,
so to speak. What about blinding? I've heard
that term before, but I'm not sure I fully grasp
what it means. Yeah, blinding is all about keeping
people in the dark about who's getting which
treatment. In a single blind trial, the patients
themselves don't know what they're receiving.
And in a double blind trial, both the patients
and the researchers who are administering the
treatment are unaware. And this really helps
prevent subconscious bias from influencing how
patients report their symptoms or even how researchers
interpret the data. So it's like removing any
chance of a placebo effect or researcher expectations
influencing the outcomes. It sounds like these
design elements, control groups, randomization,
and blinding, they're all about creating a really,
really robust foundation for the trial. But how
do we actually measure whether the drug is working?
That's where I think clinical endpoints come
in, right? You're absolutely right. Endpoints
are the specific measurements that we use to
determine whether a treatment is effective. And
one of our sources describes them as the measuring
sticks of success, which I think is a great way
to visualize it. It's all about setting a target
and then figuring out how to measure whether
we're hitting the bullseye. I love that analogy.
So are we talking about things like survival
rates or disease progression or even how patients
report they feel? Exactly, you know, there are
different types of endpoints. Some of them are
what we call hard or clinical endpoints, things
like overall survival. Those are pretty clear
cut. And then we have what are called surrogate
endpoints, which might be things like, you know,
tumor shrinkage in an oncology trial or blood
sugar control in a diabetes trial. They're not
the ultimate outcome, but they can give us an
early indication of whether the drug is having
a biological effect. And that's especially useful
in phase two, where we're looking for those early
signals of efficacy. This is like choosing the
right, you know, yardstick depending on the disease
and the treatment being studied, right? Are there
any real world examples from our sources that
might help illustrate this for people? There
are. Yeah, there was one study looking at a new
diabetes treatment and they used glucose AUC
reduction as an endpoint. Essentially, this measures
how well the drug controlled blood sugar over
a specific period of time. Now, it's a surrogate
endpoint because it's not directly measuring,
you know, how long people live or whether they
develop complications. But it gives researchers
a good indication of whether the drug is effectively
targeting the underlying disease process. That
makes it much more concrete for me. It's like
we're not just looking at the these abstract
concepts. But we're actually seeing how these
endpoints play out in a real world study. And
this brings up another question for me. How do
researchers make sure they have enough patients
in a trial to actually detect a real effect if
one exists? I've heard the term statistical power
thrown around a lot, but I'm not quite sure I
understand it. Yeah, and that's a crucial point,
and it ties into this concept of statistical
significance. You might have heard of the p -value,
which is often set at .05 in research. Basically,
it means there's less than a 5 % chance that
the results we're seeing are due to random chance.
Statistical power is the probability of actually
finding that statistically significant result
if a real effect exists. And the more patients
we have in a trial, the greater our power to
detect even small effects. So if a trial is underpowered,
It's like trying to find a needle in a haystack
with a tiny magnet. We might miss a real, potentially
beneficial effect of the drug just because we
didn't have enough patience to see it clearly.
Exactly. And that's why sample size is such a
key driver of statistical power. Of course, you
know, the magnitude of the effect we're looking
for also matters. If the drug has a huge impact,
we might be able to detect it with a smaller
sample size. But in many cases, the effects are
more subtle and we need a larger group of patients
to be confident in our findings. This is all
starting to click for me now. We talked about
the core elements of good trial design, the control
groups, randomization and blinding and how they
create a solid foundation for getting those reliable
results. Then we kind of dove into this fascinating
world of clinical endpoints. You know, those
measuring sticks that tell us whether a drug
is working, and now we're kind of starting to
grasp the importance of statistical power in
making sure our trials are sensitive enough to
detect those real effects if they exist. But
before we move on, I'm curious, what stands out
to you so far? What's sparking your curiosity?
Hold onto that thought, and we'll pick back up
in part two with even more insights into the
world of phase two clinical trials. You know,
it's fascinating how much actually goes into
designing these phase two trials, isn't it? We've
talked about, you know, controlling for bias
and selecting those right endpoints to measure
success. But there's another layer here, I think,
that's essential for making sure that these trials
are conducted to the highest possible standards,
and that's the regulatory landscape. You're right.
We can't just design these trials in a vacuum,
can we? There are guidelines and regulations
that researchers need to follow. Absolutely.
Organizations like the FDA here in the US and
the ICH, the International Council for Harmonization
globally, they provide a framework for the ethical
and scientific conduct of research, you know,
throughout all phases of drug development. So
think of them as the guardians of patient safety
and the gatekeepers for new drugs reaching the
market. So it's not just about good intentions,
right? There's an entire system in place to make
sure that these trials are done right. What kind
of guidance do these organizations provide specifically
for phase two trials? Well, their guidelines
cover a wide range of aspects. For instance,
there's the ICHE 9 guideline, which focuses on
statistical principles. It emphasizes the importance
of having a clear scientific hypothesis, selecting
appropriate endpoints, and then determining an
adequate sample size to ensure sufficient statistical
power. That makes sense. I mean, we already talked
about why statistical power is so crucial for
detecting real effects. But it's interesting
to know that this isn't just left up to chance.
There are guidelines to make sure that researchers
are doing this right. Oh absolutely, and there's
more. The ICH E6 guideline provides a framework
for good clinical practice throughout the entire
trial process. It covers everything from obtaining
informed consent from patients to ensuring the
accuracy and integrity of the data collected.
So it's like a comprehensive roadmap for conducting
ethical and scientifically sound research. Do
these guidelines also address the specific challenges
of different therapeutic areas? I mean, a trial
for let's say a new heart medication probably
has different considerations than one for a new
cancer treatment. You're spot on. And both the
FDA and the ICH have developed a whole library
of guidelines tailored to different disease areas.
For example, there are specific guidelines for
conducting trials in oncology, cardiovascular
disease, infectious diseases, and so many more.
And these guidelines really reflect the unique
challenges and considerations inherent in each
of these areas. So it sounds like a very complex
web of regulations. But ultimately, it's all
about ensuring that these clinical trials are
conducted to the highest possible standards.
Right. Precisely. And that's ultimately for the
benefit of patients. By adhering to these rigorous
standards, we increase the chances of developing
safe and effective treatments that truly improve
people's lives. That brings us back to why we're
doing all of this in the first place, right?
It's not just about scientific curiosity, but
it's about making a real difference in people's
lives. We talked earlier about statistical power
and how important it is to have enough patients
in a trial to detect a real effect. if one exists.
What are some of the challenges that researchers
face in getting those calculations right, especially
in phase two? That's a great question. And one
of the biggest challenges in phase two is that
we're often dealing with smaller sample sizes
compared to those massive phase three trials.
This means we have to be extra careful about
our assumptions going in. What kind of assumptions
are we talking about here? Well, one crucial
assumption is the estimated effect size of the
drug. So how much of a difference do we think
it will make compared to the control group? If
we overestimate that effect size, we might end
up with a trial that's underpowered and we could
miss a real effect even if it's there. So it's
like kind of setting the bar too high and then
being disappointed when the drug can't clear
it. Exactly. And on the flip side, if we underestimate
the effect size, we might end up with a trial
that's overpowered, meaning we enroll more patients
than we really need, which wastes resources,
and it could potentially expose more patients
to the risks of a new treatment unnecessarily.
Sounds like a delicate balancing act. You need
to find that sweet spot where the trial is powerful
enough to detect a real effect, but not so large
that it becomes unmanageable and expensive. Exactly.
And it's not just about effect size. We also
have to consider the variability in the data
that we're collecting. And this can be influenced
by things like the patient population, the disease
being studied, and even the measurement methods
that we're using. Right, right. So getting these
assumptions right is really crucial for making
sure that we have enough patients to see a clear
signal if the drug is truly working. This highlights
how important it is to be, I guess, a critical
reader of research, right? Just because a trial
shows a positive result doesn't necessarily mean
it's a slam dunk. We need to understand how those
results were generated and whether the trial
was designed in a way that gives us confidence
in those findings. That's like being a detective,
looking for clues to see if the evidence really
stacks up. I like that analogy. And speaking
of looking closely, let's talk about some common
misconceptions about phase two trials. A lot
of people, when they hear a clinical trial, they
think of these huge, you know, late stage studies.
But phase two is a different animal altogether.
OK, so what sets phase two apart? Well, phase
two trials are often smaller and more exploratory
than those large phase three trials. Their primary
goal is to gather that preliminary evidence of
efficacy and to identify the optimal dose and
dosing regimen for the drug. Think of it like,
you know, fine tuning a recipe before you bake
a giant cake. So it's not necessarily about proving
beyond a shadow of a doubt that the drug works,
but it's more about. getting those early signals
and figuring out the best way to administer the
treatment. Exactly. Phase two trials are designed
to provide a signal, a hint that the drug might
be effective. They help us narrow down the possibilities
and determine whether it's worth moving forward
to those larger, more expensive phase three trials.
Sometimes a phase two trial might show that the
drug isn't as effective as we initially thought
or that it has unexpected side effects. And in
those cases, it might be decided to stop the
development altogether, which saves time and
resources. It sounds like phase two is all about
gathering that crucial information to inform
those critical gone -ago decisions in the drug
development process. Precisely. And that's why
these trials are so valuable. They help us weed
out the less promising candidates and focus our
efforts on the treatments that have the greatest
potential to benefit patients. We've covered
a lot of ground in this part of our deep dive,
haven't we? We've explored the regulatory landscape
that kind of governs these trials. tackled some
common misconceptions about phase two, and delved
deeper into those complexities of statistical
power. But our exploration isn't over yet. Hold
on to those insights, and we'll pick back up
in part three with even more fascinating discussions
about the world of phase two clinical trials.
Welcome back to our deep dive. into this fascinating
world of phase two criminal trials. We've already
covered so much ground from those core principles
of trial design to the complexities of statistical
power and the crucial role of those regulatory
guidelines. But I have a feeling the conversation
is about to get. even more interesting as we
kind of explore some of those, you know, those
cutting edge trends that are really shaping the
future of drug development. Yeah, you're absolutely
right. The field of clinical research is constantly
evolving and phase two trials are really right
at the forefront of that evolution. You know,
we have new technologies, innovative therapeutic
approaches and a growing understanding of human
biology. All of those are influencing how we
design and conduct these studies. OK, I'm all
ears. What are some of the trends that are really,
you know, shaking things up in this world of
phase two trials. Well, one of the most exciting
trends, I think, is the rise of personalized
medicine. It's really a paradigm shift from that
traditional one -size -fits -all approach to
medicine. We're really moving toward treatments
that are tailored to an individual's unique genetic
makeup, their lifestyle, and even their environmental
factors. It's kind of like the difference between
buying a ready -made suit and having one custom
tailored just for you. I love that analogy. So
how does this personalized approach actually
impact the design of phase two trials? Well,
it's changing everything. Instead of enrolling
large, diverse groups of patients, we're starting
to see smaller, more targeted trials that focus
on specific subgroups of patients who are most
likely to benefit from a particular treatment.
That makes a lot of sense. It seems more efficient
and potentially more ethical too, since you're
not exposing patients to treatments that are
unlikely to work for them. Exactly. And this
trend is really closely linked to the increasing
use of biomarkers, which are essentially measurable
indicators of a biological process. And by using
these biomarkers to identify those patients who
are most likely to respond, we can increase the
efficiency and the success rate of our trials.
So biomarkers are like clues that help us predict,
I guess, which patients are most likely to benefit.
from a specific treatment. It's like having this
personalized roadmap for each patient's journey
through the trial. That's a great way to put
it. And the use of biomarkers is particularly
relevant in areas like oncology, where there's
this growing emphasis on matching patients with
the most effective chemotherapy regimens or targeted
therapies. It's incredible to think about how
much progress has been made in cancer treatment
over the past... you know, a couple of decades,
I'm guessing personalized medicine and biomarkers
are playing a huge role in those advances. Absolutely.
You know, immunotherapy, which harnesses the
power of the immune system to fight cancer, is
a prime example of personalized medicine in action.
These treatments are often tailored to the specific
genetic mutations that are present in a patient's
tumor, and this can really increase their effectiveness
and minimize those side effects. It sounds like
we're moving towards a future where treatment
is less about trial and error and it's more about
this, you know, precision targeting. I'm curious
how these trends are influencing the selection
of clinical endpoints in phase two trials. That's
a great question. And with personalized medicine,
we're seeing a greater focus on endpoints that
are more directly relevant to the individual
patient rather than just overall survival. For
example, in a trial for a new cancer treatment,
we might focus on progression -free survival,
which measures how long a patient lives without
their disease worsening. Or, you know, we might
even prioritize quality of life measures that
assess how the treatment impacts a patient's
daily functioning. So it's not just about adding
years to life, but adding life to years. Yeah.
It's a more holistic approach to measuring success.
Exactly. It reflects this growing recognition
that patient -centered care is paramount. It's
not just about extending life, but it's about
improving the quality of that life. Well said.
And speaking of groundbreaking advancements,
we can't forget about gene therapy. It seems
like it has the potential to just revolutionize
how we treat a wide range of diseases. Gene therapy
is incredibly exciting, and it involves modifying
a patient's genes to correct a defect or to introduce
a therapeutic gene. It's kind of like, you know,
rewriting the code of life itself. That's a really
powerful image. But I imagine designing these
clinical trials for gene therapies, it presents
some unique challenges, right? Absolutely. One
of the biggest challenges is determining the
durability of the treatment. You know, will that
genetic modification persist over time or will
the therapeutic effect eventually wear off? And
this is a crucial consideration when we're selecting
those endpoints and designing these trials. So
it's not just about seeing that initial response,
but you have to track those patients long term
to make sure that the treatment has lasting benefits.
That must be incredibly complex, especially for
rare diseases where you might have a very limited
number of patients. to enroll in these trials.
You're right. It's a complex endeavor. And that
complexity really just highlights the constant
evolution of clinical research. Researchers need
to be creative and adaptable in their approach,
always seeking new ways to measure success and
ensure patient well -being. This has been an
incredible journey. You know, we've gone from
those foundational elements of trial design to
the cutting edge of personalized medicine and
gene therapy. And it's clear that phase two trials
play this pivotal role in bringing new treatments
to those patients and pushing those boundaries
of medical innovation. I completely agree. And
it's important to remember that these advancements
are built on a foundation of rigorous science,
ethical conduct and a deep commitment to patient
well -being. Thank you so much for sharing your
expertise with us today. You've given us, I think,
a much deeper understanding of all the intricacies
of these Phase II clinical trials and the incredible
effort that goes into developing those safe and
effective new treatments. It's been my pleasure.
And you know, remember, knowledge is power. The
more we understand about clinical research, the
more informed decisions we can make about our
own health and the future of medicine. And until
our next deep dive, keep exploring the world
around you with curiosity and a thirst for knowledge.
There's always something new to discover.